Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model

Fig. 2

a Tumor volumes (mm3) of GL261 glioma-bearing animals either untreated (UT) or treated with anti-VEGF (n = 5) or anti-c-Met (n = 5) antibody therapies, TMZ (n = 5), or AG119 (n = 7), as measured by MRI. There was a significant decrease in tumors treated with either AG119 (***p < 0.001; p = 0.00067), TMZ (*p < 0.05; p = 0.03392), anti-VEGF (*p < 0.05; p = 0.01540) or ant-c-Met (**p < 0.01; p = 0.00539) when compared to untreated mice. b-f T2-weighted MR images of GL261 glioma-bearing mice. Tumors are outlined in red based on tumor boundary contrast with ‘normal’ brain tissue. b Representative untreated mouse (vehicle control) (21 days following GL261 cell implantation). c Anti-VEGF antibody treated mouse at 27 days after cell implantation. d Anti-c-Met antibody treated mouse at 28 days following cell implantation. ei-v TMZ-treated mice at 28–30 days following cell implantation. fi-v AG119-treated mice at 26–29 days following cell implantation. Mice were treated when tumor volumes were >10 mm3. Tumor volumes were measured by adding tumor areas in multiple 1 mm image slices. Each image is obtained from different mice in each treatment group

Back to article page